Vijay Pande, a founding general partner at a16z Bio + Health, and Julie Yoo, a fellow general partner at the same firm, explore the transformative challenges of integrating AI into healthcare. They discuss the potential of AI to streamline workflows, enhance doctor-patient interactions, and revolutionize clinical trials. The conversation touches on using AI for patient triage in emergency care and the shift towards value-based care, emphasizing the need for specialized AI models to interpret complex medical data while overcoming systemic barriers.

Join Andrew Scott, author of "The Longevity Imperative," and Vijay Pande, founding general partner of a16z Bio + Health, as they challenge the conventional views on aging. They discuss the urgent need to shift from "sick care" to proactive health management, highlighting economic implications as life expectancy rises. Explore the complexities of personalized health, the importance of dismantling ageism, and how societal perceptions of aging must evolve. Reimagine a future where longevity means more than just surviving—it's about thriving at every age.

Today’s episode is with Mark Cuban, founder of multiple businesses, owner of the Dallas Mavericks, one of the sharks on Shark Tank, and cofounder of the Mark Cuban Cost Plus Drug Company. He is joined by Vijay Pande, founding partner of a16z Bio + Health. Together, they talk market forces in healthcare, the importance of trust to patients, and Mark’s ideas to tackle the Gordian knot that is American healthcare. Listen to our last two episodes on Healthcare x Fintech:When Two Giants Intersect: Healthcare Meets FintechHow Fintech is Reshaping Our $4T Healthcare Industry Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Vijay Pande and Julie Yoo from a16z Bio + Health discuss grand challenges in healthcare AI, including AI integration in healthcare workflows, value-based care, and innovation in clinical trials. They also share their thoughts on the AI startups they hope to see in the industry.

At the end of 2022, our team at a16z asked dozens of partners across the firm to spotlight one big idea that startups in their fields could tackle in 2023.Emerging from this exercise came 40+ builder-worthy pursuits for the year, ranging from entertainment franchise games to precision delivery of medicine to small modular reactors, and of course loads of AI applications.In our 2-part series, we’ll be covering 12 of these big ideas with the partners that shared them.Here in part 2, we’ll cover Fintech, American Dynamism, and Bio & Health. Listen in as we chat with Anish Acharya, Angela Strange, Michelle Volz, Ryan McEntush, Vijay Pande, and Julie Yoo.And for the full list of 40+ ideas, check out the full article: https://a16z.com/2022/12/15/big-ideas-in-tech-2023/Topics Covered:(0:59) GPT Unlocks Credit Counseling - Anish Acharya(9:53) Compliance as a Competitive Advantage - Angela Strange(23:31) Small Modular Reactors Advance the Nuclear Renaissance - Michelle Volz(33:48) Overhauling the Space Supply Chain - Ryan McEntush(44:40) The Biggest Company in the World - Vijay Pande(51:17) The Value-Based Care Stack - Julie YooResources:https://a16z.com/2022/11/02/america-space-age/https://a16z.com/2022/11/11/the-biggest-company-in-the-world/https://a16z.com/2021/01/08/the-new-tech-stack-for-virtual-first-care/ Stay Updated: Find us on Twitter: https://twitter.com/a16zFind us on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. For more details please see a16z.com/disclosures.

Exploring the biotech revolution with Vijay Pande, discussing AI impact on drug development, challenges in biotech startups, healthcare transformation through software engineering, navigating regulatory landscapes, and the evolution of healthcare towards value-based care.

Dr. Vijay Pande and Daisy Wolf discuss AI's impact on healthcare, funding innovative companies, personalized medicine through tech, and the role of wearable devices. They explore revolutionizing healthcare with AI, optimizing health with mitochondrial supplements, and the future of mental health care. The podcast emphasizes the importance of leveraging technology for tailored and efficient healthcare delivery.

Over the last 20 years, the idea of “designing biology” has gone from science fiction to just science, as the field of synthetic biology has exploded, with applications from therapeutics to manufacturing and more. In this episode from January 2019, one of the pioneers in the field, professor James J. Collins of MIT, joins a16z general partner on the Bio + Health fund, Vijay Pande, and editorial partner Hanne Winarsky, to discuss the origins of synthetic biology or "synbio", to what "engineering and designing" biology really looks like in action and the disciplinary differences between how biologists and engineers see the world.

with @LauraDeming, @kpfortney, @vijaypande, and @omnivorousread Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives—on the verge of revolutionizing our world in ways we are only just beginning to imagine. In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer's—and increasing the amount of time we are healthy—today?  In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.

Vijay Pande and Steph Smith discuss using DNA as data storage, comparing it to Moore's Law. They explore DNA's capacity, longevity, and potential for the future of biotech. The podcast covers advancements in DNA storage, challenges in DNA synthesis, and the efficiency of using DNA for data storage.

The last few months have seen dramatic—almost magical—applications of expert generative AI released to the public. (One of those applications, incidentally, was in editing the sound mix of this episode.)But what does this mean for healthcare and bio? Vijay Pande, founding partner of a16z Bio + Health, and Marc Andreessen, cofounder of a16z, sat down for a wide-ranging discussion on AI as an additive superpower…for healthcare as well as screenplays, music, and more.You can also watch the full episode on our YouTube channel: https://www.youtube.com/@a16z.

Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives -- on the verge of revolutionizing our world in ways we are only just beginning to imagine.In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer’s -- and increasing the amount of time we are healthy -- today? In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.Be sure to subscribe to 'Bio Eats World' if you want to keep getting it (and please feel free to rate it as well). To learn more about the expanding a16z Podcast network, please visit a16z.com/podnetwork.

Vijay Pande, a general partner at a16z Bio + Health, is joined by venture partner Surya Ganguli and investing partner Bowen Liu. They dive into how AI is revolutionizing drug development, highlighting its role in identifying new targets and optimizing clinical trials. Discussions touch on the power of large datasets in advancing personalized medicine, as well as the exciting potential of using AI to merge various biological data types. Their perspectives present a captivating look at the future of health technology and research.

Vijay Pande, an expert on AI in healthcare, discusses the misconceptions surrounding the 'black box' of AI. He explains how AI can be transparent and provide evidence-based decisions. The chapter also explores the potential of AI in healthcare and the role of human professionals in managing AI workers.

Pushmeet Kohli and Vijay Pande discuss the transformative power of AI in science, focusing on AlphaFold's impact on protein structure prediction, revolutionizing biology, drug design, and research economics. They explore the accessibility of AI tools, decision-making in open-sourcing models, and the exciting future of AI advancements in scientific discovery.

Vijay Pande, founding partner of Bio + Health, discusses the evolution of AI, the pioneers in the field, and the shift to biology. He highlights the advancements in biology, the challenges of obtaining data, and the importance of multiple perspectives in understanding cells. The podcast also explores the opportunities in AI startups and how AI is being integrated into life sciences and healthcare companies.

There's no question technology played a huge role in the recent/current pandemic, including especially in the plug-and-play engineering and incredibly fast development behind the mRNA vaccines... But is there an even bigger role for the private sector, not just government, to play (and partner) when it comes to key infrastructure for future such emergencies, and even beyond?Especially given how faulty the translation of institutional science to policy and public health measures turned out to be -- for instance, with "6 feet" of social distancing, or with fomite (vs. aerosol) transmission of COVID. And why are we still talking about the same, not specific, vaccine booster for the Delta variant? What can we learn about real-world evidence, other clinical trial approaches, and progressive (vs. binary) EUA approvals when it comes to public health emergencies? Are capabilities like genomic surveillance and mapping strains -- which require layers of technology, real time -- sitting in the right places?In this special book-launch episode of the a16z Podcast, former FDA commissioner Dr. Scott Gottlieb -- author of the upcoming new book, Uncontrolled Spread: Why COVID-19 Crushed Us, and How We Can Defeat the Next Pandemic -- shares insights on the above, and revealing stories from behind the scenes. Do we need a new entity to manage public health through a national security lens, and is the government capable? Gottlieb debates this and other probing questions from a16z co-founder Marc Andreessen (who famously wrote "It's time to build"); a16z bio general partner Vineeta Agarwala MD, Phd (who has spoken about the trials of clinical trials, practiced medicine during the pandemic, and more); and founding a16z bio general partner Vijay Pande PhD (who, among other things, founded the distributed computing project Folding@Home which pivoted to COVID proteins).One thing's for sure -- with this COVID crisis, we're at an inflection point between old and new technology -- whether it's in how we make vaccines, or how we apply the fields of synthetic biology and genetic epidemiology in public health response. So now's the time to look both backward, and forward, to really change things...

In this engaging discussion, Vijay Pande, a general partner at Andreessen Horowitz specializing in health care investments, shares his transition from academia to venture capital. He discusses the transformative potential of AI in health care, addressing both challenges and opportunities. Pande emphasizes the need for interdisciplinary work between medical professionals and AI specialists to revolutionize patient care. He also dives into competitive dynamics among AI models and reflects on how AI could democratize health access, reminiscent of past technological revolutions.

Vijay Pande, a General Partner at a16z, has been pivotal in merging software engineering with life sciences. He delves into the past two decades, spotlighting the Folding@Home project and the revolutionary AlphaFold. Pande emphasizes how engineering teams can transform biology, not just through algorithms but via professional collaboration. He also discusses AI's potential in drug discovery, the value of interdisciplinary partnerships, and the hurdles startups face in integrating AI within healthcare. Expect insights into the promising future of biotechnology!

Vijay Pande and Julie Yoo, general partners at a16z with a focus on healthcare technology and AI, tackle the intriguing fusion of AI and healthcare. They discuss how AI can dramatically reduce healthcare costs while improving patient experiences. The conversation dives into the complexities of regulatory challenges and the critical need for innovative data generation over traditional methods. They explore personalized healthcare through advancements in precision medicine, highlighting how understanding patient phenotypes can revolutionize care.

Today we're continuing a series we started a while ago of read-alouds (for more context on the why and why now check out episode #500 on how we podcast!).The first was episode #544 in April, It's Time to Build, read out loud by Marc Andreessen; what follows are  three more pieces read out loud by their authors:"Why Every Company Will Become a Fintech Company: The Next Era of Financial Services and the 'AWS Phase' for Fintech" by Angela Strange"When One App Rules Them All: The Case of WeChat and Mobile in China" by Connie Chan, first published August 2015"Why We Shouldn’t Fear the ‘Black Box’ of AI (in Healthcare and Everywhere)" by Vijay Pande, first published in the New York Times January 2018 

In this episode of a16z bio Journal Club, general partner Vijay Pande, bio deal team partner Andy Tran, and bio editor Lauren Richardson discuss a novel CRISPR-Cas-based anti-viral strategy.The discussion covers the differences between this newly developed prophylactic strategy, traditional vaccines, and anti-viral drugs; how this strategy can be engineered to target a huge range of coronavirus and influenza strains; and the next steps needed to go from paper to practice:“Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza” in Cell (April 2020), by Timothy Abbott, Girija Dhamdhere, Yanxia Liu, Xueqiu Lin, Laine Goudy, Leiping Zeng, Augustine Chemparathy, Stephen Chmura, Nicholas Heaton, Robert Debs, Tara Pande, Drew Endy, Marie La Russa, David Lewis, and Lei Qia16z Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature -- what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.

We’re at a moment where we are now seeing medicine go virtual faster, and at a scale that it has never done before. In this conversation,  a16z bio general partners Vijay Pande and Julie Yoo, who come from the worlds of bio, technology and care delivery,  talk with Hanne Tidnam all about what exactly virtual care and “telemedicine” is... and what it isn’t; what it works well for, what doesn’t (yet), and where there’s potential; and finally, the current pain points (including regulation), and what we’ll learn from this current moment for the next generation of virtual medicine tools.

Mintu Turakhia, a cardiologist at Stanford and Director of the Center for Digital Health, joins Brandon Ballinger, CEO of Cardiogram, and Vijay Pande, general partner at a16z, to dive into the practical applications of AI in healthcare. They discuss the historical evolution of AI, its role in improving diagnosis and treatment, and the challenges of integrating technology into clinical practice. The trio explores the innovative uses of AI for medical data analysis, enhancing clinical trials, and the ethical dimensions of AI's role in medicine.

Luis von Ahn, the mastermind behind reCAPTCHA and Duolingo, teams up with Jay Komarneni, founder of HumanDX, and Vijay Pande from a16z. They explore how data ontologies shape collective intelligence in diverse fields like healthcare and language learning. The conversation dives into harnessing human input for AI accuracy, the complexities of knowledge sharing, and the incentives that drive collective contribution to projects like Duolingo. They also discuss how scalable knowledge systems can enhance healthcare access, emphasizing the power of collaboration between humans and machines.

Join Jeff Cordova, interim head of software engineering at Rigetti Computing, and Vijay Pande, general partner at Andreessen Horowitz, as they dive into the fascinating world of quantum computing. They discuss how quantum systems are transforming computing architecture and the importance of rethinking algorithms. The conversation explores the role of cloud technology in democratizing access to quantum power and the potential for killer apps that harness this new frontier. Get ready for an insightful expedition into the future of computing!

Frank Chen, an AI expert, Vijay Pande, a healthcare innovator, and Alex Rampell, a fintech specialist, dive into pressing tech policy debates. They tackle the implications of the American Health Care Act and discuss how tech can improve risk pooling in healthcare. The conversation shifts to the ethics of AI, addiction, and the opioid crisis, questioning whether technology can offer solutions. They also explore the weighty effects of Dodd-Frank on startups and the future of self-driving tech, revealing the intricate relationship between innovation and regulation.

Sean Duffy, CEO of Omada Health, and Vijay Pande, a16z bio fund general partner, dive into the transformative potential of digital therapeutics. They discuss how software-based solutions could complement or even replace traditional pharmaceuticals, especially for behavioral health issues. The conversation touches on the surprise effectiveness of older adults using these technologies and the importance of integrating them into healthcare. They also explore the role of AI in enhancing decision-making without replacing human touch, all while pushing towards preventive and value-based care.

Vijay Pande, a general partner at Andreessen Horowitz's bio fund, and Jeffrey Kaditz, co-founder and CEO of Q, delve into the underwhelming state of health data collection. They argue for a shift from outdated medical practices to more sophisticated, time-based diagnostics. The duo discusses the potential of using diverse data points to better predict diseases and the idea of data donations akin to organ donations. They emphasize the importance of improving diagnostics for early disease detection and envision a future powered by patient-owned health data.

Join Gabriel Otte, CEO of Freenome, Vijay Pande, a general partner at Andreessen Horowitz, and Malinka Walaliyadde, also from Andreessen Horowitz, as they dive into the complexities of genomics and disease. They explore the transition from traditional genome sequencing to machine learning in cancer detection. Tackling the interplay of numerous genes, they discuss the importance of early diagnosis and the role of innovative technologies. Hear insights on how advancements in genomics could redefine healthcare, uncovering previously misunderstood areas of the human genome.

Join Vijay Pande, a16z bio fund general partner, Jeff Kindler, former Pfizer CEO, and Andrew Radin, CEO of TwoXAR, as they dissect the intersection of computation and biology. They discuss how the mindset of 'move fast' contrasts with the slow pharmaceutical landscape. Discover how cloud computing and big data revolutionize drug development, the challenges of data sharing, and the role of AI in making healthcare more affordable. The future of healthcare relies on robust data and innovative thinking!

Join Vijay Pande, a general partner at Andreessen Horowitz focusing on biotech, and Alex Rampell, a fintech specialist also at Andreessen Horowitz, as they dissect the fascinating world of data network effects. They explore how mere data quantity isn't enough; it's all about actionable insights. The duo tackles ethical data usage, the challenges of pooling data in fintech and health, and shares strategies for startups to build meaningful network effects. Expect engaging insights on navigating the complexities of data-driven innovation!

In this engaging discussion, Vijay Pande, a Stanford professor and entrepreneur, teams up with Chris Dixon, a partner at Andreessen Horowitz, to explore how computational advancements are revolutionizing biology. They delve into the booming realm of bio startups, emphasizing the impact of affordable sensors and cloud computing. Pande highlights exciting trends like digital therapeutics and computational biomedicine. They tackle the complexities of reproducibility in research and the transformative potential of AI in enhancing medical solutions.

Herman Narula, CEO of Improbable, leads a pioneering company focused on simulation platforms for complex systems, while Vijay Pande, a Stanford professor and expert in computational biology, explores groundbreaking innovations. They delve into the limitations of traditional data processing frameworks and propose simulations as a solution for modeling complex phenomena. Topics include disaster planning, healthcare, and urban environments, showcasing how advanced computing can transform decision-making and reveal hidden behaviors in intricate systems.